NCT06746298Not yet recruiting
A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer
Source: ClinicalTrials.gov · Last updated 24 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective study of expression profiling-based assessment of the efficacy of neoadjuvant therapy for rectal cancer.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 118 (estimated)
- First submitted
- 17 Dec 2024
- Start date
- 1 Jan 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- Shanghai Minimally Invasive Surgery Center
- Diseases
- Colorectal cancer
- NCT number
- NCT06746298
What you commit to
- Study type: Observational
- Planned participants: 118
- From 1 Jan 2025 to the primary completion date, 31 May 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Samples are not collected, stored, or processed in accordance with specified requirements
- Sample does not meet the requirements for subsequent RNA-seq testing
- Cases enrolled with a subsequent diagnosis other than rectal adenocarcinoma.
- The patient refuses or is unable to complete the entire neoadjuvant treatment
- Lack of post-neoadjuvant imaging results and lack of routine postoperative pathology results.
- Other patients who, in the judgment of the investigator, do not meet the enrollment requirements
Who the study is looking for
- Age ≥18 years, male or infertile female
- Patients with rectal adenocarcinoma diagnosed by colonoscopic biopsy
- Neoadjuvant therapy according to guideline recommendations
- Endoscopic biopsy with access to biopsy tissue for subsequent RNA-seq testing
- Patients who do not have a combination of primary malignant tumors elsewhere.
- Patients who understand the purpose of the trial, participate voluntarily and sign an informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.